BENITEC BIOPHARMA INC (BNTC)
Health Care · Gene therapy / RNA interference therapeutics · NASDAQ
Benitec is a clinical-stage gene therapy company developing DNA-directed RNA interference (ddRNAi) treatments delivered via adeno-associated viral vectors to potentially provide "one-shot" cures for genetic diseases.
What BENITEC BIOPHARMA INC does
Benitec Biopharma is a gene therapy company focused on developing and commercializing DNA-directed RNA interference (ddRNAi) product candidates using adeno-associated viral (AAV) vectors as delivery systems. The company is pursuing a pipeline of clinical and preclinical programs, with revenue primarily derived from licensing and collaboration agreements rather than product sales. Benitec aims to develop therapies that could provide durable or potentially curative treatment effects from a single administration.
Themes: Gene therapy, RNA interference / RNAi therapeutics, Genetic disease treatment, One-shot / curative therapeutics, AAV vector technology
Fundamentals
- Price$13.48 as of 2026-08-21 close
- Market cap$463M as of 2026-08-21
- 1-year return+6.1% 2025-08-21 close $12.70 → 2026-08-21 close $13.48
- P/En/a negative earnings
- Net margin-20671.4% as of 2026-08-24
- Gross margin+100.0% as of 2026-08-24
- ROE-45.9% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue CAGR (3y)-93.0% SEC XBRL
- Beta0.25 as of 2026-08-24
- Last reported earnings2026-05-14 SEC EDGAR Form 8-K (Item 2.02)
How BNTC compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How BENITEC BIOPHARMA INC looks technically
BENITEC BIOPHARMA INC (BNTC) is trading 10.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 6 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 10 trading days ago. It is 19.6% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 10.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +10.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.56 | $12.56 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.20 | $12.20 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 13.955. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 6 trading days ago — a "golden cross", a bullish long-term signal | 6 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 10.5% above | +10.4% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 15.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 58.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($11.88 to $13.98) — its "stochastic" reading is 76 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 76.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $16.76 | $16.76 |
|---|---|---|
| From the 52-week high | it is 19.6% below its 52-week high (its highest price of the past year) | -19.6% |
| Above the 52-week low | it is 36.9% above its 52-week low (its lowest price of the past year) | +36.9% |
| Below the 52-week high | it is 19.6% below its highest point of the past year | 19.6% |
| Since a 20-day breakout | it made a new 20-day high about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day high about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $5916.00 (set on 2014-06-24) | $5916.00 |
| Given back of the 52-week move | over the past year its closes ranged ($10.06 to $16.52), and it has recovered around half of its fall from last year’s high — 53% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $14.05 to $14.26. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 52.9% |
| From the all-time high | it is 99.8% below its all-time high | -99.8% |
| Nearest price level | it is trading 1.0% above a support level at $13.34 — a price it turned at twice since 2024-12-17, most recently on 2026-03-09. Since 2024-08-21 it has 10 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.0% |
| All-time low | its lowest closing price on record is $1.86 (set on 2023-08-09) | $1.86 |
| Above the all-time low | it is 624.7% above its all-time low | +624.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 33rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8298 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8298 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.37 and $14.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.37 – $12.69 – $14.01 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 1.5 daily ranges above its 200-day average price (10.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.14× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | 8 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 8 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.0% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-08-05 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.0 percentage points (the stock gained 13.4% while the market gained 2.3%) | +11.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 15.6 percentage points (the stock gained 18.7% while the market gained 3.1%) | +15.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 15.6 percentage points (the stock gained 26.7% while the market gained 11.1%) | +15.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 14.3 percentage points (the stock gained 6.1% while the market gained 20.5%) | -14.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.5% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.6% of the share price. | +6.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 13% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $11.96 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +12.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% above the average price paid since it last reported on 2026-05-14 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $12.32 — a volume-weighted average of daily closes over 67 sessions, not a true tick-by-tick VWAP. | +9.4% |
Price levels it has turned at before
BNTC last closed at $13.48 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.34 | Support | 1.0% below the last close | turned there twice · 2024-12-17 to 2026-03-09 |
| $13.82 | Resistance | 2.6% above the last close | turned there three times · 2025-12-05 to 2026-08-11 |
| $13.01 | Support | 3.5% below the last close | turned there 7 times · 2024-10-01 to 2026-02-03 |
| $14.28 | Resistance | 6.0% above the last close | turned there 8 times · 2025-04-22 to 2026-06-25 |
| $12.33 | Support | 8.5% below the last close | turned there four times · 2025-02-04 to 2025-11-17 |
| $16.83 | Resistance | 24.9% above the last close | turned there twice · 2025-03-21 to 2025-10-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $13.96.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · trendless / choppy (low ADX) · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.14 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$24.17 range $16.00 – $32.00; median $24.50
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Clinical trial execution risk: timing and sufficiency of patient enrollment, dosing, and trial data availability; regulatory approval uncertainty from FDA","Funding and capital adequacy: ongoing losses, ongoing need for additional financing to execute business plan, and material weakness identified in internal controls over financial reporting","Intellectual property and competitive risk: ability to protect and enforce patents, dependence on collaboration partners, and market acceptance competition"]
What changed in the latest 10-Q
AI-assisted comparison of BNTC's 10-Q filed 2026-05-14 against the prior one filed 2026-02-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'Special Note Regarding Forward-Looking Statements' immediately prior to Part I, Item 1 in the newer filing (2026-05-14)
- Added phrase 'Orphan Drug Designation and Fast Track Designation in the United States' in BB-301 description (newer filing)
- Added text describing single-vector approach with hyphen: 'single-vect or approach' appearing in newer filing (2026-05-14)
- Removed:
- Removed 'Oculopharyngeal Muscular Dystrophy (OPMD)' full name reference in the context of diseases like OPMD, replacing with just 'OPMD' (older filing had full name; newer has abbreviated)
- Removed text 'Several companies, including Alnylam Pharmaceuticals Inc. ("Alnylam"), utilize this approach in their RNAi product candidates.' from end of siRNA explanation section (older filing)
- Removed text 'Importantly, many' which appears to be the start of a sentence at the end of older filing excerpt
- Reworded:
- Changed 'Orphan Drug Designation in the United States and the European Union' to 'Orphan Drug Designation in the European Union and Orphan Drug Designation and Fast Track Designation in the United States' (order and detail revision)
- Changed 'Modified adeno-associated viral (" AAV ") vectors' to 'Modified adeno-associated viral (" AAV ") vectors' - spacing appears consistent but context notes earlier use of 'Modified AAV vectors' without the full expansion in newer version
- Changed reference from 'like Oculopharyngeal Muscular Dystrophy (OPMD)' to 'like OPMD' (abbreviation only in newer filing)
- Notes:
- The newer filing text appears truncated at the end, cutting off mid-sentence in the siRNA section, limiting full assessment of later changes
- Text formatting inconsistency noted in newer filing: 'single-vect or' appears to have irregular spacing that may be a transcription artifact
- Comparison is limited to the provided excerpts; full MD&A sections may contain additional changes not visible in these samples
Risk Factors
- Added:
- Newer filing (2026-05-14) references 'Annual Report on Form 10-K for the year ended June 30, 2025' in the forward-looking statements section; older filing (2026-02-12) references 'this Report' instead.
- Newer filing shows balance sheet as of March 31, 2026; older filing shows balance sheet as of December 31, 2025.
- Newer filing shows consolidated statements of operations for 'Nine Months Ended March 31' periods; older filing shows 'Six Months Ended December 31' periods.
- Reworded:
- Older filing (2026-02-12) states 'the identified material weakness in our internal controls over financial reporting'; newer filing (2026-05-14) states 'the identified material weakness in our internal control over financial reporting' (changed from plural 'controls' to singular 'control').
- Opening phrase in forward-looking statements: older filing (2026-02-12) reads 'This Report contains forward-looking statements that are subject to'; newer filing (2026-05-14) reads 'This Report contains forward-looking statements within the meaning of the federal securities laws that are subject to'.
- Risk factors reference language: older filing references 'other risks detailed under the caption "Risk Factors" in this Report and in other reports'; newer filing references 'other risks detailed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended June 30, 2025 and other reports'.
- Notes:
- The two filings cover different fiscal periods (March 31, 2026 vs. December 31, 2025), so financial statement figures differ naturally by time period.
- The forward-looking statements section wording changes are minimal and primarily involve clarifications and reference updates rather than substantive risk factor changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2025-12-29. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BNTC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding BNTC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,697,366
- Reported value $18,076,947
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BNTC had 2,146,708 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BNTC had 6.25% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 26.74 days to cover at the same settlement.
- Reported short interest (shares) 2,146,708
- Short interest (% of shares outstanding) 6.25%
- Prior settlement (shares) 2,269,662
- Reported change -5.42%
- Days to cover (reported) 26.74
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alnylam Pharmaceuticals (ALNY)
- Arrowhead Pharmaceuticals (ARWR)
- Dicerna Pharmaceuticals (now part of Novo Nordisk)
- Intellia Therapeutics (NTLA)
- Editas Medicine (EDIT)
- CRISPR Therapeutics (CRSP)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BNTC vs…
BENITEC BIOPHARMA INC is found in…
BNTC ranks in…
Frequently asked questions
What does BENITEC BIOPHARMA INC (BNTC) do?
Benitec Biopharma is a gene therapy company focused on developing and commercializing DNA-directed RNA interference (ddRNAi) product candidates using adeno-associated viral (AAV) vectors as delivery systems. The company is pursuing a pipeline of clinical and preclinical programs, with revenue primarily derived from licensing and collaboration agreements rather than product sales.
What sector is BENITEC BIOPHARMA INC (BNTC) in?
BENITEC BIOPHARMA INC (BNTC) is classified in the Health Care sector. Its industry is Gene therapy / RNA interference therapeutics. It trades on NASDAQ.
Who are BENITEC BIOPHARMA INC's (BNTC) competitors?
Notable peers of BENITEC BIOPHARMA INC (BNTC) include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals (now part of Novo Nordisk), Intellia Therapeutics and Editas Medicine. This peer set is informational only — not financial advice.
Is BENITEC BIOPHARMA INC (BNTC) overbought or oversold right now?
BENITEC BIOPHARMA INC (BNTC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BNTC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.